PBYI — PUMA BIOTECHNOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401667 ·
Last close
$7.23
Market Cap
$368.00M
52W High
$7.90
52W Low
$5.95
ADV30
247,153
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 44,814,000 | 34,390,000 | -3,828,000 | -3,753,000 | 192,699,000 | 36,193,000 | 64,283,000 |
| Dec 2025 | 75,453,000 | 52,326,000 | 17,106,000 | 13,438,000 | 216,302,000 | 29,635,000 | 85,962,000 |
| Sep 2025 | 54,475,000 | 42,302,000 | 9,573,000 | 8,844,000 | 202,862,000 | 53,525,000 | 87,594,000 |
| Jun 2025 | 52,436,000 | 40,135,000 | 6,636,000 | 5,855,000 | 194,916,000 | 54,662,000 | 90,198,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,802,000
Investing CF
$-36,188,000
Financing CF
$-45,198,000
CapEx
$-123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,283,775,000
Inventory
$5,515,000
Receivables
$53,654,000
ST Investments
$67,893,000
EBIT TTM
$42,404,000
Pretax Income TTM
$35,782,000
Interest Exp TTM
$6,622,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$227,178,000
EBITDA
$39,413,000
Free Cash Flow
$44,085,376
Enterprise Value
$299,208,896
Total Cash
$101,545,000
Total Debt
$15,954,000
Shares Out
50,899,456
Trailing EPS
$0.48
Book Value
$2.52
ROE
21.6%
ROA
9.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 228,371,000 | 37,299,000 | 31,111,000 | 216,302,000 | 85,962,000 | — | 41,802,000 |
| Dec 2024 | 230,468,000 | 30,966,000 | 30,278,000 | 213,333,000 | 121,208,000 | — | 38,918,000 |
| Dec 2023 | 235,637,000 | 32,640,000 | 21,591,000 | 230,528,000 | 177,086,000 | — | 27,009,000 |
| Dec 2022 | 228,031,000 | 30,720,000 | 2,000 | 222,059,000 | 200,451,000 | — | -15,827,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $7.56 · call volume: 39 · put volume: 3Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | $367.55M | $12.64 | — |
| VSTM | Verastem, Inc. | $366.43M | $4.17 | — |
| CYDY | CytoDyn Inc. | $369.83M | $0.27 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $365.80M | $3.35 | — |
| FBRX | Forte Biosciences, Inc. | $360.22M | $17.59 | — |
News headlines (Yahoo Finance, 1h cache)
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
2026-06-11 15:48 · Yahoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-06-03 21:00 · Yahoo
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
2026-05-14 12:04 · Yahoo
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
2026-05-11 13:04 · Yahoo
Puma (PBYI) Q1 2026 Earnings Call Transcript
2026-05-08 20:14 · Yahoo
Puma Biotechnology Q1 Earnings Call Highlights
2026-05-08 19:12 · Yahoo
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
2026-05-08 16:03 · Yahoo
Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 23:05 · Yahoo
Puma Biotechnology Reports First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.